

**IPR and Innovation**

1. [Glenmark Pharmaceuticals' Finacea generic infringes Bayer patent: US court](#) - Economic Times

**Medical & Regulatory**

1. [Finally, a policy scanner for these devices](#) – Hindu Business Line
2. [Indian government task force calls to simplify clinical trials process](#) – Outsourcing Pharma

**Others**

1. [India may contest EU move to ban 700 drugs](#) - Economic Times

**IPR and Innovation**

1. [Glenmark Pharmaceuticals' Finacea generic infringes Bayer patent: US court](#) - Economic Times  
Glenmark Pharmaceuticals' proposed generic version of Bayer AG's Finacea, a gel for treating the common skin condition rosacea, infringes Bayer's patent, a US court ruled on Monday. The federal court in Wilmington, Delaware said Glenmark's proposed gel would be absorbed into the skin in a similar way to Finacea, violating Bayer's patent.

**Medical & Regulatory**

1. [Finally, a policy scanner for these devices](#) – Hindu Business Line  
Medical equipment may not be treated on the same footing as drugs — a step in the right direction. Nearly a decade after the government first announced its intentions to regulate the domestic medical device industry, a comprehensive draft National Medical Device Policy (NMDP-2015) has been issued and made public for review by interested stakeholders. Medical devices form a \$200 billion global industry, which develops and manufactures essential healthcare equipment ranging in complexity from simple devices such as thermometers and stethoscopes to complex devices like pacemakers, ultrasound machines and surgical robots.
2. [Indian government task force calls to simplify clinical trials process](#) – Outsourcing Pharma  
As the number of approved clinical trials in India continues to taper off compared to years past, a government task force is now calling for a new expedited trial approval process.

**Others**

1. [India may contest EU move to ban 700 drugs](#)– Economic Times  
India may contest a decision by the European drug regulator to recommend a ban on as many as 700 generic products tested by GVK Biosciences at its Hyderabad facility, citing it as a restriction on trade. The decision, which was reiterated by the European Medicines Agency last week, will become legally binding if the European Commission accepts it and possibly set back India's pharma exports by at least \$1 billion.